6 News & Press Releases found
DiscGenics, Inc. News
-
DiscGenics Announces Presentation of Positive Interim Clinical Data from Phase 1/2 Study of Cell Therapy for Degenerative Disc Disease
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection; improvements ...
-
DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration as US Study Achieves One-Year Follow-up Milestone
DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it has completed ...
-
Keeping our Patients and Colleagues Safe During the Ongoing COVID-19 Pandemic
At DiscGenics, we are actively monitoring developments in the ongoing coronavirus (COVID-19) pandemic and recommendations from the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and Utah Department of Health. As ...
-
DiscGenics Announces Completion of Enrollment in U.S. Phase 1/2 Clinical Trial of Discogenic Cell Therapy for Degenerative Disc Disease
DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it has completed ...
-
Japanese Clinical Study of DiscGenics` Cell Therapy for Disc Degeneration Passes Initial Safety Review
Salt Lake City, UT and Tokyo, Japan – January 7, 2020 – DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with ...
-
DiscGenics Announces Publication of Preclinical Data for Disc Degeneration Treatment in The Spine Journal
Salt Lake City, UT – September 24, 2019 – DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with ...